Schrecker, Christopher
Schulze, Falko
Trojan, Jörg
Bechstein, Wolf Otto
Zeuzem, Stefan
Koch, Christine
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 10 February 2024
Accepted: 16 March 2024
First Online: 11 April 2024
Declarations
:
: Jörg Trojan reports consulting fees, speaker fees, or grant support from Amgen, AstraZeneca, Bayer Healthcare, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Institute for Quality and Efficiency in Health Care (IQWiG), Ipsen, Lilly ImClone, Merck/MSD, Merck Serono, PCI Biotech, Roche, and Servier. Wolf Otto Bechstein reports consulting fees, speaker fees, or travel support from Astellas, Chiesi, Deutscher Ärzteverlag, Else Kröner-Fresenius-Stiftung, ESOT, Falk Foundation, Gesundheit Österreich GmbH, Gore Deutschland, Medac, MCI Deutschland, Novartis, Sanofi, Sanofi Genzyme, Sirtex, Springer, and Terumo. Stefan Zeuzem reports consulting fees or speaker fees from AbbVie, Gilead, Intercept, Janssen, Merck/MSD, and Sobi. Christine Koch reports consulting fees, speaker fees, or travel support from Eisai, Elsevier, Ipsen, Medac, Merck/MSD, Novartis, Roche, and Servier. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; in the decision to publish the results.
: The study was approved by the institutional review board of the University Hospital Frankfurt (reference number SGI-4-2019). The research was conducted in accordance with the World Medical Association Declaration of Helsinki.
: Written informed consent was obtained from all patients involved in the study unless patients died before consent could be obtained, in which case the requirement for consent was waived by the institutional review board to avoid a selection bias.